AU2013251079B2 - Methods for treating Parkinson's disease - Google Patents

Methods for treating Parkinson's disease Download PDF

Info

Publication number
AU2013251079B2
AU2013251079B2 AU2013251079A AU2013251079A AU2013251079B2 AU 2013251079 B2 AU2013251079 B2 AU 2013251079B2 AU 2013251079 A AU2013251079 A AU 2013251079A AU 2013251079 A AU2013251079 A AU 2013251079A AU 2013251079 B2 AU2013251079 B2 AU 2013251079B2
Authority
AU
Australia
Prior art keywords
dopa
rats
radiprodil
tozadenant
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013251079A
Other languages
English (en)
Other versions
AU2013251079A1 (en
Inventor
Bernard Christophe
Patrick Downey
Anne MICHEL
Florian MONTEL
Dieter Scheller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of AU2013251079A1 publication Critical patent/AU2013251079A1/en
Application granted granted Critical
Publication of AU2013251079B2 publication Critical patent/AU2013251079B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013251079A 2012-04-20 2013-04-19 Methods for treating Parkinson's disease Ceased AU2013251079B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636054P 2012-04-20 2012-04-20
US61/636,054 2012-04-20
PCT/EP2013/058212 WO2013156614A1 (en) 2012-04-20 2013-04-19 Methods for treating parkinson's disease

Publications (2)

Publication Number Publication Date
AU2013251079A1 AU2013251079A1 (en) 2014-11-06
AU2013251079B2 true AU2013251079B2 (en) 2017-03-23

Family

ID=48182898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013251079A Ceased AU2013251079B2 (en) 2012-04-20 2013-04-19 Methods for treating Parkinson's disease

Country Status (9)

Country Link
US (2) US9387212B2 (OSRAM)
EP (1) EP2838530B1 (OSRAM)
JP (1) JP6042968B2 (OSRAM)
KR (1) KR20140146217A (OSRAM)
CN (1) CN104321057B (OSRAM)
AU (1) AU2013251079B2 (OSRAM)
CA (1) CA2869216A1 (OSRAM)
ES (1) ES2627541T3 (OSRAM)
WO (1) WO2013156614A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
EP3237399B1 (en) 2014-12-23 2022-11-30 Avalo Therapeutics, Inc. Compounds, compositions and methods
CN107849010B (zh) * 2015-06-01 2021-11-09 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物
WO2017136375A1 (en) * 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
CN106214652A (zh) * 2016-08-31 2016-12-14 安徽省润生医药股份有限公司 一种含有伊曲茶碱的药物组合物
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
CN108864114B (zh) 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
WO2025137652A2 (en) 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116026A1 (en) * 2004-05-24 2005-12-08 F. Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
WO2010022304A1 (en) * 2008-08-21 2010-02-25 Forest Laboratories Holdings Limited Methods for treating cns disorders

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258827B1 (en) * 1995-05-26 2001-07-10 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective NMDA antagonists
EP1016407B1 (en) * 1997-09-05 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating brain ischemia
EP1178835A4 (en) 1999-05-10 2002-08-21 Univ Princeton COMPOSITIONS AND METHODS FOR IMPROVING LEARNING AND REMEMBERABILITY
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6362196B1 (en) 1999-10-29 2002-03-26 Merck & Co., Inc. Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
GB0015488D0 (en) 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
JP2004501901A (ja) 2000-06-26 2004-01-22 メルク　エンド　カムパニー　インコーポレーテッド イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬
AU2001277273A1 (en) 2000-07-27 2002-02-13 Washington University Methods and agents for treating persistent pain
WO2002012892A2 (en) 2000-08-04 2002-02-14 Cis Biotech, Inc. Rapid multiple panel of biomarkers in laboratory blood tests for tia/stroke
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
DE60210944T3 (de) 2001-02-23 2015-07-23 Merck Sharp & Dohme Corp. N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
CA2449249A1 (en) 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
KR100890676B1 (ko) 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
WO2003084931A1 (en) 2002-04-02 2003-10-16 Merck & Co., Inc. 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20060160853A1 (en) 2002-11-22 2006-07-20 Mccauley John A 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003303042A1 (en) 2002-12-17 2004-07-09 Pfizer Inc. 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CA2521907A1 (en) 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
EP1648882B1 (en) 2003-06-04 2008-08-06 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2005019222A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
CN1835953A (zh) 2003-08-15 2006-09-20 默克专利 4－环烷基氨基吡唑并嘧啶nmda/nr2b拮抗剂
EP1666464A4 (en) 2003-09-25 2008-12-10 Shionogi & Co PIPERIDINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NDMA RECEPTOR
WO2005035522A1 (en) 2003-10-08 2005-04-21 Pfizer Japan, Inc. 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists
JP2007508288A (ja) 2003-10-08 2007-04-05 ファイザー株式会社 縮合ラクタム化合物
WO2005080317A2 (en) 2004-02-11 2005-09-01 Pfizer Japan, Inc. Therapeutic amide derivatives
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
JP2008509139A (ja) 2004-08-03 2008-03-27 メルク エンド カムパニー インコーポレーテッド １，３−二置換ヘテロアリールｎｍｄａ／ｎｒ２ｂ拮抗薬
US20090041751A1 (en) 2005-02-01 2009-02-12 University Of Medicine And Dentistry Of New Jersey Sepsis Prevention Through Adenosine Receptor Modulation
WO2006113471A2 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
WO2006124770A2 (en) 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
WO2006129626A1 (ja) 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
WO2006137465A1 (ja) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
CA2615147A1 (en) 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
US7799947B2 (en) 2005-11-29 2010-09-21 Hammersmith Imanet Limited In vivo imaging compounds
WO2007063839A1 (ja) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
ES2339502T3 (es) * 2006-06-26 2010-05-20 Schering Corporation Antagonistas del receptor a2a de adenisina.
WO2008055711A2 (en) 2006-11-09 2008-05-15 Centre De Recherche Public De La Sante Use of an adenosine antagonist
US8304198B2 (en) 2007-06-19 2012-11-06 Rajiv Gandhi Centre For Biotechnology Assay for detection of transient intracellular CA2+
JPWO2009025265A1 (ja) 2007-08-21 2010-11-25 塩野義製薬株式会社 ピペラジン誘導体
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
JP2011500819A (ja) 2007-10-24 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アリルインデノピリミジン及びアデノシンＡ２ａ受容体拮抗物質としてのそれらの使用
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
BRPI0909378A2 (pt) 2008-03-27 2015-10-06 Evotec Neurosciences Gmbh métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b
US8684624B2 (en) 2008-07-01 2014-04-01 Saint-Gobain Performance Plastics Rencol Limited Tolerance ring
EP2144462A1 (en) 2008-07-09 2010-01-13 Nokia Siemens Networks OY Reduced resource allocation parameter signalling
EP2297715A1 (de) 2008-07-09 2011-03-23 Siemens Aktiengesellschaft Verfahren, kommunikationsverbund und software zum auffinden von gesuchten objekten
US20100086483A1 (en) 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy
WO2010040003A2 (en) 2008-10-01 2010-04-08 The Scripps Research Institute Human a2a adenosine receptor crystals and uses thereof
US8282042B2 (en) 2009-06-22 2012-10-09 The Boeing Company Skin panel joint for improved airflow
US8301311B2 (en) 2009-07-06 2012-10-30 Siemens Aktiengesellschaft Frequency-responsive wind turbine output control
US20110007639A1 (en) 2009-07-10 2011-01-13 Qualcomm Incorporated Methods and apparatus for detecting identifiers
US20110105540A1 (en) 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
DE102010026274A1 (de) 2010-07-06 2012-01-12 Voith Patent Gmbh Bremsanlage und Verfahren zum Einstellen eines Bremsmomentes einer solchen
JP5843869B2 (ja) 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116026A1 (en) * 2004-05-24 2005-12-08 F. Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
WO2010022304A1 (en) * 2008-08-21 2010-02-25 Forest Laboratories Holdings Limited Methods for treating cns disorders

Also Published As

Publication number Publication date
EP2838530A1 (en) 2015-02-25
AU2013251079A1 (en) 2014-11-06
JP2015514739A (ja) 2015-05-21
EP2838530B1 (en) 2017-04-05
US20150157638A1 (en) 2015-06-11
ES2627541T3 (es) 2017-07-28
HK1202457A1 (en) 2015-10-02
JP6042968B2 (ja) 2016-12-14
US9387212B2 (en) 2016-07-12
WO2013156614A1 (en) 2013-10-24
US20160367560A1 (en) 2016-12-22
CN104321057A (zh) 2015-01-28
ES2627541T8 (es) 2017-11-23
KR20140146217A (ko) 2014-12-24
CN104321057B (zh) 2016-09-14
CA2869216A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AU2013251079B2 (en) Methods for treating Parkinson's disease
US10004744B2 (en) Therapeutic approaches for treating Parkinson's disease
AU2013248685B2 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
ES2765200T3 (es) Tratamiento de efectos secundarios de trastornos motores y de movimiento asociados a tratamientos de la enfermedad de Parkinson
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
JP6145946B2 (ja) 併用ａｌｓ療法
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
US7888341B2 (en) Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
WO2022159629A1 (en) Combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation- related dysfunction exists
TWI723012B (zh) 額葉功能障礙之治療劑
HK1202457B (en) Methods for treating parkinson's disease
Domino et al. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced hemiparkinsonian monkeys
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
OA18659A (en) Therapeutic Agent for Frontal Lobe Dysfunction.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired